GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lyell Immunopharma LYEL · USD

Health Care · US listing · 🇺🇸 United States

Compare

15.42

+3.77%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$36,000

FY2019FY2025

Net income

−$274.4m

FY2019FY2025

Free cash flow

−$150.8m

FY2019FY2025

Shareholders' equity

$248.2m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$36,000$61,000$130,000$84.7m$10.7m$7.8m$657,000
Research and development$158.7m$171.6m$182.9m$159.2m$138.7m$182.2m$63.6m
Operating income−$203.8m−$358.8m−$247.0m−$187.1m−$214.8m−$211.9m−$102.1m
Net income−$274.4m−$343.0m−$234.6m−$183.1m−$250.2m−$204.5m−$129.4m
Diluted earnings per share-16.14-26.38-18.05-15.26-35.75-204.47-10.49

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$340.1m$490.9m$750.0m$937.6m$1.13bn$908.3m$555.6m
Cash and short-term investments$247.2m$370.5m$546.2m$640.2m$614.8m$612.6m$436.0m
Total liabilities$91.8m$108.0m$95.1m$104.3m$197.6m$189.8m$147.6m
Shareholders' equity$248.2m$382.8m$655.0m$833.3m$929.8m$718.4m$408.1m
Shares outstanding17m13m13m12m7m1m12m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$150.0m−$162.4m−$163.7m−$169.6m−$126.2m−$160.9m$39.5m
Capital spending−$780,000−$464,000−$2.7m−$24.3m−$65.5m−$51.5m−$16.0m
Free cash flow−$150.8m−$162.9m−$166.4m−$193.8m−$191.8m−$212.4m$23.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$4,000$2,000$6,000$15,000$8,000$7,000$11,000$34,000
Operating income−$47.3m−$46.2m−$61.3m−$37.3m−$47.1m−$57.4m−$201.1m−$50.5m
Net income−$44.8m−$24.2m−$140.7m−$38.8m−$42.7m−$52.2m−$191.9m−$44.6m
Diluted earnings per share-1.92-1.10-8.28-2.29-2.51-3.07-14.76-3.43
Cash from operations−$33.0m−$38.0m−$32.0m−$28.0m−$34.0m−$54.0m−$47.0m−$35.0m
Total assets$311.2m$350.6m$340.1m$408.0m$385.5m$429.8m$490.9m$619.2m
Cash and short-term investments$204.1m$254.0m$247.2m$319.6m$276.8m$301.2m$370.5m$440.5m
Debt—$9.4m$9.1m$8.8m$8.5m$8.2m$8.0m$7.1m
Shareholders' equity$233.8m$273.7m$248.2m$329.1m$298.9m$336.5m$382.8m$530.7m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-92.5%-65.9%—
Operating income2.9%-0.8%—
Net income14.4%6.1%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-579926.8%-1173.7%-1377.6%—
Net margin-636538.1%-1219.2%-1442.1%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-1.9-0.5-1.4-2.9-2.8
Price to sales———6.365.1

Share price return

Finished calendar years

20252024202320222021
Return172%-55%-32%-60%-55%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-to-1 reverse split · 2 Jun 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.